Sergio Quezada

Professor of Cancer Immunology and Immunotherapy, Co-founder of Achilles Therapeutics

University College London

Professor Sergio Quezada earned a PhD from Dartmouth Medical School, where his research focused on the mechanisms for the induction of transplantation tolerance. Following postdoctoral research at Memorial Sloan-Kettering Cancer Center, in 2011 he joined the University College London Cancer Institute as head of the Immune Regulation and Tumor Immunotherapy group. His research group at UCL focuses in the study of the mechanism of action of immune-modulatory antibodies targeting co-inhibitory and co-stimulatory pathways and used as novel anticancer therapies. He holds several patents in the field of cancer immunology, is scientific co-founder of Achilles Therapeutics and scientific advisor to several companies including TUSK Therapeutics, Morphosys and KSQ therapeutics. He has been the recipient of numerous awards and most recently he was awarded with a Cancer Research UK Senior Cancer Research Fellowship.